A study for patients with non-small cell lung cancer, squamous type, who have received one course of chemotherapy and require further treatment.
- The study compares Docetaxel chemotherapy with or without Buparlisib
- For patients with stage IIIB or IV non-small cell lung cancer who have received one course of a platinum-containing chemotherapy.
- Investigational drug, Buparlisib, is provided by the study
Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.
